Meet GCT President Dr. Jeffrey Apter at the ISCTM Annual Meeting in Paris this Saturday
Having participated as Principal Investigator in over 150 trials in Depression, Anxiety, Bipolar Disorder, Schizophrenia and Alzheimer’s Disease, Dr. Apter is a welcome guest at the Meeting. Dr. Apter plans to discuss innovative solutions, promising current developments and recent trends in clinical trials industry in the Eastern Europe with his colleagues and fellow researchers. Since a new office has been opened lately in Mumbai, India, we invite those operating in this region to meet GCT President at the ISCTM Annual Meeting to share ideas and perspectives.
Serving as a forum to fundamentally re-evaluate current concepts of CNS drug development, the International Society for CNS Clinical Trials and Methodology deals with the strategic aspects of clinical trial design, other methodological issues and regulatory issues that confound CNS drug development.
Being one of the leading causes of death, Alzheimer’s disease affects millions of people daily. World’s most prominent researchers fasten upon discovering effective treatments and preventive strategies to fight this debilitating malady. 2017 ISCTM Annual Meeting discussions revolve among other topics around development of treatments for Agitation and Apathy in Alzheimer’s disease, Behavioral and Psychiatric Symptoms in Dementia, negative symptoms in Schizophrenia.
Updated: September 1, 2017